Halle/Saale, March 08th 2011 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer’s disease (AD), today announced that its innovative research on the onset of AD and its consequences for novel treatment options will be endorsed by a series of posters and presentations on this year’s 10th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2011), taking place in Barcelona, Spain, during March 9-13.

The company will present new results from its labs in Halle and at Ingenium GmbH in Munich as well as results from its collaboration with international academic institutions, such as the Universities of Göttingen and of Leipzig, Germany, and University of Virginia, Charlottesville and Brigham and Women’s Hospital, Boston, USA.

Hans-Ulrich Demuth, CSO of Probiodrug, stated: ”Looking at the conference program it becomes evident that Probiodrug’s pioneering work on delineating the role of pyroglutamated amyloid (pEβ or pGluAβ in AD is gaining considerable attention and broadening, resulting in more than two dozen posters and presentations on the topic”.